Can Thiopurines Prevent Formation of Antibodies Against Tumor Necrosis Factor Antagonists After Failure of These Therapies

RAY KIRAN BOYAPATI, Gwo-Tzer Ho, Jack Satsangi

Research output: Contribution to journalEditorialpeer-review

Abstract

Anti-tumor necrosis factor α (anti-TNF) therapy has revolutionised the treatment of Crohn’s disease (CD). However, primary nonresponse occurs in an estimated 13-40% of patients1 and secondary loss of response in 23%-46% of patients after 12 months2. A challenging and important aspect of anti-TNF management is therefore to avoid the development of nonresponse, and identify/manage secondary nonresponse if it occurs.
Original languageEnglish
JournalClinical Gastroenterology and Hepatology
Early online date5 Oct 2016
DOIs
Publication statusE-pub ahead of print - 5 Oct 2016

Fingerprint

Dive into the research topics of 'Can Thiopurines Prevent Formation of Antibodies Against Tumor Necrosis Factor Antagonists After Failure of These Therapies'. Together they form a unique fingerprint.

Cite this